الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 84 |  |  |
| | | from | 84 | | |
Abstract
The present study was designed to investigate the possible prophylactic and therapeutic effects of carvedilol and cilostazol onliver fibrosis in rats. 50 adult male albino rats were used. They were divided into 5 groups, each group consisting of 10 rats. TAA was used to induce liver fibrosis. It was given by intraperitoneal injection in a dose of 200 mg/kg twice weekly for 6 weeks. Advanced liver fibrosis occurred, confirmed by biochemical evaluation. group I served as negative control group. While, group II received I.P injection of TAA in a dose of 200 mg/kg, twice weekly for 6 weeks which served as positive control group. group III received carvedilol orally (10 mg/kg) daily for 4 weeks then given together with TAA (200 mg/kg) by I.P injection, twice weekly for another 6 weeks.group IV received cilostazol orally (30 mg/kg) daily for 4 weeks then given together with TAA (200 mg/kg) by I.P injection, twice weekly for another 6 weeks.group V received both carvedilol orally (10 mg/kg) daily and cilostazol orally (30 mg/kg) daily for 4 weeks then given together with TAA (200 mg/kg) by I.P injection, twice weekly for another 6 weeks.
group III which received carvedilol orally (10 mg/kg) daily for 4 weeks then given together with TAA (200 mg/kg) by I.P injection, twice weekly for another 6 weeks showed a significant decrease in the serum levels of ALT, AST, TNF-α, MDA compared to positive control group. There was also a significant increase in tissue levels of GPx compared to positive control group.
group IV which received cilostazol orally (30 mg/kg) daily for 4 weeks then given together with TAA (200 mg/kg) by I.P injection, twice weekly for another 6 weeks showed a significant decrease in the serum levels of ALT, AST, TNF-α, MDA compared to positive control group. There was also a significant increase in tissue levels of GPx compared to positive control group.
group V, which received both carvedilol orally (10 mg/kg) daily and cilostazol orally (30 mg/kg) daily for 4 weeks then given together with TAA (200 mg/kg) by I.P injection, twice weekly for another 6 weeks. resulted in a decrease in the serum levels of ALT, AST, TNF-α, MDA compared to group II (TAA), group III (carvedilol), group IV(cilostazol). There was also an increase in tissue levels of GPx compared to group II (TAA), group III (carvedilol), group IV (cilostazol).
It could be concluded that carvedilol, cilostazol had a significant prophylactic effect which will be more if combined together that evidenced through improving the biochemical parameters in relation to positive control group.
Therefore, carvedilol, cilostazol may be considered as potential antifibrotic drugs which need further experimental and clinical investigation for clinical application.